Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia.

24 Jul 2015

$Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients$

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

End-stage renal disease (ERSD) is the last stage of chronic kidney disease where the kidneys function at under 10 to 15 percent of their normal capacity. At this stage, kidneys cannot effectively remove waste or excess fluid from the blood system, and dialysis or a kidney transplant is necessary to live.

14 Jul 2015

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.

13 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

Study: Genes may not trigger heart disease in people suffering from migraine with aura

A new study suggests that genes may not be to blame for the increased risk of heart disease some studies have shown in people with migraine, especially those with migraine with aura. The research is published during Headache/Migraine Awareness Month in the inaugural issue of the journal Neurology Genetics, an open access, or free to the public, online-only, peer-reviewed journal from the American Academy of Neurology.

3 Jul 2015

ACT intervention may be effective in reducing risk for cardiovascular disease

A controlled study published in the current issue of Psychotherapy and Psychosomatic indicates the usefulness of a brief behavioral intervention targeting psychological risk factors for vascular disease.

24 Jun 2015

Small intestine causes chronic inflammation in obese patients

Obesity is caused by numerous and complex factors, some of which are as yet unsuspected. Scientists from the CNRS, INSERM, UPMC and Université Paris Descartes, working with research clinicians from Paris Public Hospitals (AP-HP) have now shown that severe obesity is accompanied by inflammation of the small intestine and enhanced immune response in that region.

22 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

Study: Rheumatoid arthritis nearly doubles risk of surprise heart attack

Patients with rheumatoid arthritis are at increased risk of a surprise heart attack, according to new research presented today at ICNC 12 by Dr Adriana Puente, a cardiologist in the National Medical Centre "20 de Noviembre" ISSSTE in Mexico City, Mexico.

5 May 2015

Study suggests link between androgens, atherosclerosis and obesity in females

While testosterone replacement therapies may be controversial in males, new research in The FASEB Journal may extend this controversy to females too. That's because research involving mice, appearing in the April 2015 issue, suggests that there is an association between low levels of androgens (which includes testosterone), and atherosclerosis and obesity in females.

2 Apr 2015

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

31 Mar 2015

Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

Amgen today announced that an application seeking marketing approval of Repatha (evolocumab) for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan.

21 Mar 2015

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions.

19 Mar 2015

Liraglutide may help obese adults achieve weight loss

Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes.

7 Mar 2015

Medicare Part D, adherence can help save patients with high cholesterol

According to the Centers for Disease Control and Prevention, one in three American adults has high cholesterol. For those struggling with high cholesterol, getting needed prescriptions and adhering to the prescribed treatment regimen is critical.

28 Feb 2015

Ninety percent of patients at risk of CHD fail to receive statins

The study, published in Current Medical Research and Opinion, provides the first ever real-world view of the treatment landscape for patients at risk of CHD[1], with a sample of two million patients. But the results paint a bleak picture of prescribing patterns with the majority not being given the potentially life saving drug.

27 Feb 2015

Ildong Pharmaceutical to market BELVIQ (lorcaserin HCl) for weight management in South Korea

Arena Pharmaceuticals, Inc. today announced that Ildong Pharmaceutical Co., Ltd., has informed Arena that the Ministry of Food and Drug Safety has approved BELVIQ (lorcaserin HCl) for marketing for weight management in South Korea. Ildong will market and distribute BELVIQ in South Korea under its marketing and supply agreement with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH.

3 Feb 2015

Study reveals how the brain can use fatty acids to control liver lipid production

Ways of keeping the heart healthy has widened, with the discovery that the brain can help fight off hardening of the arteries.

31 Jan 2015

Upregulating heme-oxygenase with hemin helps improve pericardial adipocyte morphology, function

Scientists at the University of Saskatchewan College of Medicine, Department of Physiology, Saskatoon, Canada, led by Dr. Joseph Fomusi Ndisang have determined that upregulating heme-oxygenase with hemin improves pericardial adipocyte morphology and function.

27 Jan 2015